Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 4/20 | 0.38 |
| ▸ | DDR1 | Q08345 | 14/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23389100 | 0.86 | ROCK2 (0.44) | BTKDDR1ROCK2 | |
| SCHEMBL23389097 | 0.86 | ROCK2 (0.44) | BTKDDR1ROCK2 | |
| SCHEMBL23389149 | 0.86 | BTK (0.37) | BTKDDR1ROCK2PDE2A | |
| SCHEMBL23389146 | 0.86 | BTK (0.37) | BTKDDR1ROCK2PDE2A | |
| SCHEMBL29943304 | 0.85 | DRD4 (0.32) | DDR1 | |
| SCHEMBL23389135 | 0.85 | DRD4 (0.32) | DDR1 | |
| SCHEMBL23418993 | 0.85 | DRD4 (0.32) | DDR1 | |
| SCHEMBL25994875 | 0.85 | DRD4 (0.32) | BTKDDR1ROCK2 | |
| SCHEMBL23389182 | 0.81 | KMT2A (0.44) | BTK | |
| SCHEMBL23389179 | 0.81 | KMT2A (0.44) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202974-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202974-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | CASP6, CASP1, CASP10 | BTK 3023/4885DDR1 1956/4885ROCK2 3549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.